Dr. Michael J. Mauro - CML - Chronic myeloid leukemia
Dr. Michael J. Mauro is a hematologist in New York, New York and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Geisel School of Medicine at Dartmouth and has been in practice for more than 20 years
Extract of US News
VIDEOS
ASH 2021: Good News for CML Treatment
December 21, 2021, Patient Power
CML Expert Discusses How to Protect Yourself From Coronavirus - Dr. Mauro
April 6, 2020, Patient Power
Fourth generation TKIs for CML: asciminib (Dr. Michael Mauro)
September 13, 2018, VJHemOnc – Video Journal of Hematological Oncology
Dr. Michael Mauro: An Expert Answers Your CML Questions
January 29, 2018, Patient Power
Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial
January 10, 2017, VJHemOnc – Video Journal of Hematological Oncology
Dr. Mauro on Selecting Therapies for Patients With CML
January 15, 2016, OncLiveTV
Michael Mauro Discusses Therapy-Free CML Remission
December 31, 2015, OncLiveTV
Dr. Michael Mauro on Toxicities of TKI Usage in CML Patients
December 4, 2015, Targeted Therapy
Michael J. Mauro on Questions From Patients With CML
November 18, 2015, curetoday
ASH Meeting on Hematologic Malignancies: Michael Mauro, MD
March 31, 2015, American Society of Hematology
Dr. Michael Mauro on Treatment Discontinuation for CML
February 13, 2015, OncLiveTV
2014 Annual Hematology Meeting: CML
December 10, 2014, ImedexCME
Considerations for Patients Taking Ponatinib - Michael Mauro, MD, NCMLS Medical Advisor
November 5, 2013, The National CML Society
An Interview with Dr. Michael Mauro (OHSU)
January 24, 2011, The National CML Society
ASH 2021: Good News for CML Treatment
December 21, 2021, Patient Power
CML Expert Discusses How to Protect Yourself From Coronavirus - Dr. Mauro
April 6, 2020, Patient Power
Fourth generation TKIs for CML: asciminib (Dr. Michael Mauro)
September 13, 2018, VJHemOnc – Video Journal of Hematological Oncology
Dr. Michael Mauro: An Expert Answers Your CML Questions
January 29, 2018, Patient Power
Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial
January 10, 2017, VJHemOnc – Video Journal of Hematological Oncology
Dr. Mauro on Selecting Therapies for Patients With CML
January 15, 2016, OncLiveTV
Michael Mauro Discusses Therapy-Free CML Remission
December 31, 2015, OncLiveTV
Dr. Michael Mauro on Toxicities of TKI Usage in CML Patients
December 4, 2015, Targeted Therapy
Michael J. Mauro on Questions From Patients With CML
November 18, 2015, curetoday
ASH Meeting on Hematologic Malignancies: Michael Mauro, MD
March 31, 2015, American Society of Hematology
Dr. Michael Mauro on Treatment Discontinuation for CML
February 13, 2015, OncLiveTV
2014 Annual Hematology Meeting: CML
December 10, 2014, ImedexCME
Considerations for Patients Taking Ponatinib - Michael Mauro, MD, NCMLS Medical Advisor
November 5, 2013, The National CML Society
An Interview with Dr. Michael Mauro (OHSU)
January 24, 2011, The National CML Society
PUBLICATIONS, AUDIOS, ...
What's on the Horizon for Chronic Myeloid Leukemia?
September 27, 2017, Leukemia & Lymphoma Society
What's on the Horizon for Chronic Myeloid Leukemia?
September 27, 2017, Leukemia & Lymphoma Society
ARTICLES
Ask the Expert: Michael J. Mauro, MD on Treatment-Free CML After TKI Therapy
July 12, 2018, Medpage Today
State of CML Treatments
July 25, 2013. Cancer Network
Ask the Expert: Michael J. Mauro, MD on Treatment-Free CML After TKI Therapy
July 12, 2018, Medpage Today
State of CML Treatments
July 25, 2013. Cancer Network
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).